Baseline characteristic | Time to first relapse aHR (95% CI) p value | Time to confirmed disability progression aHR (95% CI) p value |
---|---|---|
Male sex | 0.89 (0.62 to 1.29) 0.550 | 1.36 (0.94 to 1.99) 0.106 |
Age (units=10 years) | 0.75 (0.62 to 0.92) 0.005 | 1.32 (1.08 to 1.62) 0.008 |
EDSS | 0.87 (0.80 to 0.95) 0.001 | 1.04 (0.95 to 1.13) 0.400 |
Disease duration (years) | 1.00 (0.96 to 1.03) 0.862 | 1.00 (0.97 to 1.03) 0.886 |
Number of prebaseline DMT starts | 1.02 (0.87 to 1.20) 0.772 | 1.09 (0.93 to 1.27) 0.273 |
Proportion disease duration on treatment | 0.49 (0.19 to 1.25) 0.133 | 0.35 (0.12 to 1.01) 0.052 |
DMT stopped: Avonex (IFNb 1a IM) | Reference | Reference |
Betaseron (IFNb 1b) | 1.51 (0.92 to 2.46) 0.101 | 2.10 (1.19 to 3.72) 0.011 |
Copaxone (Glatiramer acetate) | 1.28 (0.73 to 2.25) 0.393 | 1.50 (0.71 to 3.17) 0.283 |
Rebif (IFNb 1a SC) | 1.41 (0.87 to 2.28) 0.162 | 1.49 (0.82 to 2.73) 0.192 |
The number of DMT stoppers with post-baseline relapse was 155 (36.4%) and that for post-baseline confirmed disability progression was 131 (30.8%). DMT, disease modifying therapy; EDSS, Expanded Disability Status Scale; IFNb, Interferon β; IM, intramuscular; SC, subcutaneous.